Ritonavir
- Generic Name
- Ritonavir
- Brand Names
- Kaletra, Norvir, Paxlovid, Viekira Pak, Ritonavir Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C37H48N6O5S2
- CAS Number
- 155213-67-5
- Unique Ingredient Identifier
- O3J8G9O825
- Background
Ritonavir is an HIV protease inhibitor that interferes with the reproductive cycle of HIV. Although it was initially developed as an independent antiviral agent, it has been shown to possess advantageous properties in combination regimens with low-dose ritonavir and other protease inhibitors. It is now more commonly used as a booster of other protease inhibi...
- Indication
Ritonavir is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.
...
- Associated Conditions
- Chronic hepatitis C genotype 1a, Chronic hepatitis C genotype 1b, Human Immunodeficiency Virus Type 1 (HIV-1) Infection, Mild, moderate Novel Coronavirus Infectious Disease (COVID-19)
- Associated Therapies
- -
Immunologic and Virologic Consequences of Long-Term Highly Active Antiretroviral Therapy (HAART) in Subjects With Moderately Advanced HIV-1 Disease: A Follow-Up Study to ACTG 315
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 34
- Registration Number
- NCT00000891
- Locations
- 🇺🇸
Case Western Reserve Univ, Cleveland, Ohio, United States
🇺🇸Univ of Colorado Health Sciences Ctr, Denver, Colorado, United States
🇺🇸Rush Presbyterian - Saint Luke's Med Ctr, Chicago, Illinois, United States
A Study to Compare Two Anti-HIV Combination Therapies Each Containing Saquinavir in HIV-Positive Children
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-29
- Target Recruit Count
- 50
- Registration Number
- NCT00000913
- Locations
- 🇺🇸
Emory Univ Hosp / Pediatrics, Atlanta, Georgia, United States
🇺🇸Cook County Hosp, Chicago, Illinois, United States
🇺🇸Chicago Children's Memorial Hosp, Chicago, Illinois, United States
Drug Interactions of Amprenavir and Efavirenz, in Combination With a Second Protease Inhibitor, in HIV-Negative Volunteers
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 90
- Registration Number
- NCT00005762
- Locations
- 🇺🇸
Stanford CRS, Palo Alto, California, United States
🇺🇸University of Colorado Hospital CRS, Aurora, Colorado, United States
🇺🇸Indiana Univ. School of Medicine, Infectious Disease Research Clinic, Indianapolis, Indiana, United States
A Comparison of Three Drug Combinations Containing Clarithromycin in the Treatment of Mycobacterium Avium Complex (MAC) Disease in Patients With AIDS
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 246
- Registration Number
- NCT00001058
- Locations
- 🇺🇸
Indiana Univ. School of Medicine, Infectious Disease Research Clinic, Indianapolis, Indiana, United States
🇺🇸Methodist Hosp. of Indiana, Indianapolis, Indiana, United States
🇺🇸Harbor-UCLA Med. Ctr. CRS, Torrance, California, United States
Effectiveness and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) in HIV Patients Who Have Never Received Treatment
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Glaxo Wellcome
- Target Recruit Count
- 300
- Registration Number
- NCT00005017
- Locations
- 🇺🇸
Jaime Hernandez, Research Triangle Park, North Carolina, United States
Ritonavir and Agenerase Treatment for Patients Who Have Failed Previous Anti-HIV Treatment
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Gathe, Joseph, M.D.
- Registration Number
- NCT00006591
- Locations
- 🇺🇸
Gathe, Joseph, M.D., Houston, Texas, United States
A Study of 1592U89 in Combination With Protease Inhibitors in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Glaxo Wellcome
- Target Recruit Count
- 80
- Registration Number
- NCT00002440
- Locations
- 🇺🇸
Yale U / New Haven Med Ctr / AIDS Clinical Trials Unit, New Haven, Connecticut, United States
🇺🇸Vanderbilt Univ Med Ctr, Nashville, Tennessee, United States
🇺🇸UCSD Treatment Ctr, San Diego, California, United States
Safety and Effectiveness of an Anti-HIV Drug Combination Taken Twice Daily
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 80
- Registration Number
- NCT00002241
- Locations
- 🇺🇸
Chelsea Village Med Ctr, New York, New York, United States
🇺🇸St Lukes / Roosevelt Hosp / HIV Center, New York, New York, United States
🇺🇸Univ of California at San Francisco Gen Hosp, San Francisco, California, United States
The Safety and Effectiveness of Indinavir Plus Ritonavir Plus Two NRTIs in HIV-Infected Patients Who Need Early Intervention Treatment
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 100
- Registration Number
- NCT00005118
- Locations
- 🇺🇸
Chicago Ctr for Clinical Research, Chicago, Illinois, United States
🇺🇸Bisher Akil, Los Angeles, California, United States
🇺🇸Institute of Human Virology, Baltimore, Maryland, United States
A Phase IIIB Open-Label, Comparative Study to Evaluate Saquinavir Soft Gel Capsule (SGC) Treatment in Combination With Other Antiretrovirals in HIV-1 Infected Antiretroviral-Naive Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 375
- Registration Number
- NCT00002178
- Locations
- 🇺🇸
Dr Charles Farthing, Los Angeles, California, United States
🇺🇸Community Research Initiative, Brookline, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.